Home The Word Brain	My Amedeo FAQ Privacy About
	As of October 2023, Amedeo had 12,263 active subscribers

Hepatitis

Free Subscription Articles published in J Hepatol Retrieve available abstracts of 268 articles: HTML format

Single Articles

November 2023
1. COLASANTI O, Burm R, Huang HE, Riedl T, et al
   Corrigendum to "Comparison of HAV and HCV infections in vivo and in vitro reveals distinct patterns of innate immune evasion and activation" [J Hepatol (2023) 645-656].
   J Hepatol. 2023 Nov 30:S0168-8278(23)05282-0. doi: 10.1016/j.jhep.2023.
   PubMed    
   
   
   
2. 
   The adjusted prevalence of hepatitis delta virus (HDV) in 25 countries and territories.
   J Hepatol. 2023 Nov 27:S0168-8278(23)05285-6. doi: 10.1016/j.jhep.2023.
   PubMed     Abstract available
   
   
   
3. BALAGOPAL A, Thomas DL
   Genomics on the road to functional cure of hepatitis B.
   J Hepatol. 2023 Nov 18:S0168-8278(23)05276-5. doi: 10.1016/j.jhep.2023.
   PubMed    
   
   
   
4. HUPPE D, Wedemeyer H, Cornberg M
   Population-based screening works: Effect of integrating screening for hepatitis B and C into the general health check-up in Germany.
   J Hepatol. 2023 Nov 3:S0168-8278(23)05234-0. doi: 10.1016/j.jhep.2023.
   PubMed    
   
   
   October 2023
5. PATMORE LA, van Eekhout KMA, Buti M, Koc OM, et al
   Hepatocellular carcinoma risk in Sub-Saharan African and Afro-Surinamese individuals with chronic hepatitis B living in Europe.
   J Hepatol. 2023 Oct 26:S0168-8278(23)05219-4. doi: 10.1016/j.jhep.2023.
   PubMed     Abstract available
   
   
   
6. GUAN G, Zhang T, Ning J, Tao C, et al
   Higher TP53BP2 expression is associated with HBsAg loss in peginterferon-alpha-treated patients with chronic hepatitis B.
   J Hepatol. 2023 Oct 17:S0168-8278(23)05175-9. doi: 10.1016/j.jhep.2023.
   PubMed     Abstract available
   
   
   
7. PANDURANGI S, Malik A, Owens J, Valencia CA, et al
   Deleterious variants in TNFAIP3 are associated with type II and seronegative Pediatric autoimmune hepatitis.
   J Hepatol. 2023 Oct 9:S0168-8278(23)05156-5. doi: 10.1016/j.jhep.2023.
   PubMed    
   
   
   
8. GRONBAEK L, Gronbaek H
   Editorial: Hepatocellular carcinoma in autoimmune hepatitis remains rare.
   J Hepatol. 2023 Oct 9:S0168-8278(23)05159-0. doi: 10.1016/j.jhep.2023.
   PubMed    
   
   
   
9. COLAPIETRO F, Maisonneuve P, Lytvyak E, Beuers U, et al
   Incidence and predictors of hepatocellular carcinoma in patients with autoimmune hepatitis.
   J Hepatol. 2023 Oct 4:S0168-8278(23)05095-X. doi: 10.1016/j.jhep.2023.
   PubMed     Abstract available
   
   
   
10. LU W
    A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: Need a closer look!
    J Hepatol. 2023 Oct 3:S0168-8278(23)05142-5. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    September 2023
11. CHUN HS, Papatheodoridis GV, Lee M, Lee HA, et al
    PAGE-B incorporating moderate HBV DNA levels predicts risk of HCC among patients entering into HBeAg-positive chronic hepatitis B.
    J Hepatol. 2023 Sep 19:S0168-8278(23)05096-1. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    
12. UZUN S, Zinner CP, Beenen AC, Alborelli I, et al
    Morphologic and molecular analysis of liver injury after SARS-CoV-2 vaccination reveals distinct characteristics.
    J Hepatol. 2023;79:666-676.
    PubMed     Abstract available
    
    
    
13. PERON JM, Larrue H, Izopet J, Buti M, et al
    The pressing need for a global HEV vaccine.
    J Hepatol. 2023;79:876-880.
    PubMed     Abstract available
    
    
    August 2023
14. YU X, Long J, Xie Y, Zhang J, et al
    Immunomodulatory effects of tenofovir disoproxil fumarate and entecavir in treating hepatitis B virus infection.
    J Hepatol. 2023 Aug 18:S0168-8278(23)05061-4. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    
15. WAN YM, Wu HM, Huang SQ, Li HY, et al
    A comment on "A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B." (J Hepatol. 2023 May;78(5):926-936.).
    J Hepatol. 2023 Aug 11:S0168-8278(23)05051-1. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    
16. DAI CY, Batsaikhan B, Huang CF
    'One-stop-shop' point-of-care hepatitis C RNA testing intervention in the prison: some issues.
    J Hepatol. 2023 Aug 8:S0168-8278(23)05050-X. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    
17. 
    EASL Clinical Practice Guidelines on acute-on-chronic liver failure.
    J Hepatol. 2023;79:461-491.
    PubMed     Abstract available
    
    
    
18. DEVARBHAVI H, Asrani SK, Arab JP, Nartey YA, et al
    Global burden of liver disease: 2023 update.
    J Hepatol. 2023;79:516-537.
    PubMed     Abstract available
    
    
    July 2023
19. GANE EJ, Kim W, Lim TH, Tangkijvanich P, et al
    First-in-human randomized study of RNAi therapeutic RG6346 for chronic hepatitis B virus infection.
    J Hepatol. 2023 Jul 29:S0168-8278(23)05005-5. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    
20. MARTIN MT, Patel S, Chacra W
    Pellet-based hepatitis C virus treatment with glecaprevir/pibrentasvir: a case report of an adult with short bowel syndrome.
    J Hepatol. 2023 Jul 27:S0168-8278(23)04997-8. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    
21. TOSTI ME, Caminada S, Ferrigno L
    Risk of parenterally transmitted hepatitis following exposure to invasive procedures in Italy: SEIEVA surveillance 2000-2021: authors' reply to comments.
    J Hepatol. 2023 Jul 27:S0168-8278(23)04999-1. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    
22. LENS S, Perez Del Pulgar S, Forns X
    The relevance of finding biomarkers to identify the best candidates for nucleos(t)ide analogue discontinuation in HBeAg-negative chronic hepatitis B.
    J Hepatol. 2023 Jul 27:S0168-8278(23)04994-2. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    
23. LEMPP FA, Volz T, Cameroni E, Benigni F, et al
    Potent broadly neutralizing antibody VIR-3434 controls hepatitis B and D virus infection and reduces HBsAg in humanized mice.
    J Hepatol. 2023 Jul 15:S0168-8278(23)04978-4. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    
24. KLOTZ W, Herold M
    How to test antinuclear antibodies to diagnose autoimmune hepatitis.
    J Hepatol. 2023 Jul 13:S0168-8278(23)04983-8. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    
25. GUAN MC, Ding Q, Zhu H
    Which risk model can better predict hepatocellular carcinoma in hepatitis B patients with an antiviral treatment duration of over one year ?
    J Hepatol. 2023 Jul 4:S0168-8278(23)04937-1. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    
26. OKAMOTO T, Okajima H, Ogawa E, Yurugi K, et al
    The protective association of HLA-B*52:01, HLA-C*12:02, and DQB1*06:01 alleles with severe acute hepatitis of unknown origin in Japanese children.
    J Hepatol. 2023 Jul 3:S0168-8278(23)04930-9. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    
27. DE MARTIN E, Laurent-Bellue A, Routier E, Samuel D, et al
    Acute cholestatic hepatitis in a patient with metastatic melanoma.
    J Hepatol. 2023;79:e13-e15.
    PubMed    
    
    
    
28. JACHS M, Mandorfer M, Reiberger T
    Reply to: "3P and 5P models of limited value for the detection of clinically significant portal hypertension in patients with hepatitis delta".
    J Hepatol. 2023;79:e49-e50.
    PubMed    
    
    
    
29. JAGADISAN B, Verma A, Deheragoda M, Deep A, et al
    Outbreak of indeterminate acute liver failure in children with adenoviraemia - Not a new disease.
    J Hepatol. 2023;79:43-49.
    PubMed     Abstract available
    
    
    June 2023
30. YANG F, Fan X, Yang L
    Dysregulation of the lysophosphatidylcholine/autotaxin/lysophosphatidic acid axis in autoimmune hepatitis is associated with monocyte activation.
    J Hepatol. 2023 Jun 29:S0168-8278(23)04934-6. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    
31. YANG H, Kim JH, Han JW, Lee SK, et al
    Reply to: 'A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: has the correct patient cohort been targeted?'.
    J Hepatol. 2023 Jun 27:S0168-8278(23)00425-7. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    
32. MINAMI T, Sato M, Toyoda H, Yasuda S, et al
    Machine learning for individualized prediction of hepatocellular carcinoma development after the eradication of hepatitis C virus with antivirals.
    J Hepatol. 2023 Jun 24:S0168-8278(23)00424-5. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    
33. GHANY MG, Buti M, Lampertico P, Lee HM, et al
    Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV/HDV treatment endpoints conference.
    J Hepatol. 2023 Jun 21:S0168-8278(23)00417-8. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    
34. THOMPSON LA, Plitt SS, Doucette K, Coffin CS, et al
    Evaluation and comparison of risk-based and universal prenatal HCV screening programs in Alberta, Canada.
    J Hepatol. 2023 Jun 20:S0168-8278(23)00419-1. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    
35. FAN R, Chen L, Zhao S, Yang H, et al
    Novel, high accuracy models for hepatocellular carcinoma prediction based on longitudinal data and cell-free DNA signatures.
    J Hepatol. 2023 Jun 9:S0168-8278(23)00416-6. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    
36. GANE E, Lim YS, Kim JB, Jadhav V, et al
    Evaluation of RNAi Therapeutics VIR-2218 and ALN-HBV for Chronic Hepatitis B: Results From Randomized Clinical Trials.
    J Hepatol. 2023 Jun 6:S0168-8278(23)00352-5. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    
37. KHAN RS, Lalor PF, Thursz M, Newsome P, et al
    The role of neutrophils in alcohol-related hepatitis.
    J Hepatol. 2023 Jun 6:S0168-8278(23)00346-X. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    
38. PATEL S, Moser A, Domingo H
    Sustained virologic response in DAA-treated HCV patients on anti-epileptic drugs.
    J Hepatol. 2023 Jun 2:S0168-8278(23)00347-1. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    
39. GERMANI G, Mathurin P, Lucey MR, Trotter J, et al
    Early liver transplantation for severe acute alcohol-related hepatitis after more than a decade of experience.
    J Hepatol. 2023;78:1130-1136.
    PubMed     Abstract available
    
    
    May 2023
40. DENG H, Pan Y
    The influence of invasive procedures on acute HBV and HCV infections.
    J Hepatol. 2023 May 10:S0168-8278(23)00326-4. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    
41. ANDRADE RJ, Aithal GP, de Boer YS, Liberal R, et al
    Nomenclature, Diagnosis and Management of Drug-induced Autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report.
    J Hepatol. 2023 May 8:S0168-8278(23)00320-3. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    
42. 
    Clinical Practice Guidelines on Hepatitis Delta Virus.
    J Hepatol. 2023 May 5:S0168-8278(23)00317-3. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    
43. VAN BOMMEL F, Stein K, Heyne R, Petersen J, et al
    A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B.
    J Hepatol. 2023;78:926-936.
    PubMed     Abstract available
    
    
    April 2023
44. KONDILI LA, Rumi MG, Craxi A
    Hospital HCV elimination in addition to universal precautions could reduce incidence and infection burden in Italy.
    J Hepatol. 2023 Apr 28:S0168-8278(23)00310-0. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    
45. COLASANTI O, Burm R, Huang HE, Riedl T, et al
    Comparison of HAV and HCV infections in vivo and in vitro reveals distinct patterns of innate immune evasion and activation.
    J Hepatol. 2023 Apr 28:S0168-8278(23)00309-4. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    
46. HOLLNBERGER J, Liu Y, Xu S, Chang S, et al
    No virologic resistance to bulevirtide monotherapy detected in patients through 24 weeks treatment in phase II and III clinical trials for chronic hepatitis delta.
    J Hepatol. 2023 Apr 27:S0168-8278(23)00313-6. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    
47. SHEEHAN Y, Cunningham EB, Cochrane A, Byrne M, et al
    A 'one-stop-shop' point-of-care hepatitis C RNA testing intervention to enhance treatment uptake in a reception prison: the PIVOT study.
    J Hepatol. 2023 Apr 26:S0168-8278(23)00242-8. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    
48. EL-KASSAS M, Emadeldeen M, Hassany M, Esmat G, et al
    A randomized controlled trial of SOF/VEL/VOX with or without ribavirin for retreatment of chronic hepatitis C.
    J Hepatol. 2023 Apr 21:S0168-8278(23)00234-9. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    
49. CROUCHET E, Baumert TF
    Unraveling the role of the liver myeloid compartment during hepatitis C virus cure.
    J Hepatol. 2023 Apr 21:S0168-8278(23)00239-8. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    
50. AGUILAR-BRAVO B, Arino S, Blaya D, Pose E, et al
    Hepatocyte dedifferentiation profiling in alcohol-related liver disease identifies CXCR4 as a driver of cell reprogramming.
    J Hepatol. 2023 Apr 21:S0168-8278(23)00236-2. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    
51. 
    Hepatitis D double reflex testing of all hepatitis B carriers in low HBV and high HBV/high HDV prevalence countries.
    J Hepatol. 2023 Apr 6:S0168-8278(23)00206-4. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    
52. WANG L, Zhu Q, Zhang JD, Zhang Y, et al
    Discovery of a first-in-class orally available HBV cccDNA inhibitor.
    J Hepatol. 2023;78:742-753.
    PubMed     Abstract available
    
    
    
53. ZHANG F, Xu LD, Zhang Q, Wang A, et al
    Targeting proteostasis of the HEV replicase to combat infection in preclinical models.
    J Hepatol. 2023;78:704-716.
    PubMed     Abstract available
    
    
    March 2023
54. TOSETTI G, Degasperi E, Farina E, Primignani M, et al
    Carvedilol to reduce the risk of decompensation in patients with compensated cirrhosis: really needed also in patients with HCV cured or HBV suppressed viral cirrhosis?
    J Hepatol. 2023 Mar 30:S0168-8278(23)00203-9. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    
55. CUI A, Li B, Wallace MS, Gonye ALK, et al
    Single-cell atlas of the liver myeloid compartment before and after cure of chronic viral hepatitis.
    J Hepatol. 2023 Mar 25:S0168-8278(23)00190-3. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    
56. CAMINADA S, Mele A, Ferrigno L, Alfonsi V, et al
    Risk of parenterally transmitted hepatitis following exposure to invasive procedures in Italy: SEIEVA surveillance 2000-2021.
    J Hepatol. 2023 Mar 17:S0168-8278(23)00177-0. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    
57. CARSON JM, Barbieri S, Matthews GV, Dore GJ, et al
    Corrigendum to 'National trends in retreatment of HCV due to reinfection or treatment failure in Australia' (J Hepatol [2023] 260-270).
    J Hepatol. 2023 Mar 8:S0168-8278(23)00109-5. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    
58. MONTALI I, Berti CC, Morselli M, Acerbi G, et al
    Deregulated intracellular pathways define novel molecular targets for HBV-specific CD8 T cell reconstitution in chronic hepatitis B.
    J Hepatol. 2023 Mar 7:S0168-8278(23)00167-8. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    
59. RICCIUTO A, Kamath BM, Hirschfield GM, Trivedi PJ, et al
    Primary sclerosing cholangitis and overlap features of autoimmune hepatitis: a coming of age or an age-ist problem?
    J Hepatol. 2023 Mar 2:S0168-8278(23)00162-9. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    February 2023
60. ENGELMANN C, Jalan R
    Authors' reply to: G-CSF exacerbates liver injury in a mouse model of autoimmune hepatitis.
    J Hepatol. 2023 Feb 25:S0168-8278(23)00110-1. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    
61. LOHSE AW, Lorgensen MH
    Paediatric Autoimmune Hepatitis: time to change the textbooks?
    J Hepatol. 2023 Feb 23:S0168-8278(23)00105-8. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    
62. RODRIGUEZ C, Marchand S, Sessa A, Cappy P, et al
    Orthohepevirus C hepatitis, an underdiagnosed disease?
    J Hepatol. 2023 Feb 18:S0168-8278(23)00096-X. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    
63. CHALASANI N, Li YJ, Dellinger A, Navarro V, et al
    Clinical features, outcomes, and HLA risk factors associated with nitrofurantoin-induced liver injury.
    J Hepatol. 2023;78:293-300.
    PubMed     Abstract available
    
    
    
64. CARLSON S, Vaz K, Peterson A
    A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: has the correct patient cohort been targeted?
    J Hepatol. 2023 Feb 1:S0168-8278(23)00074-0. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    January 2023
65. ZOULIM F, Testoni B
    Eliminating cccDNA to cure Hepatitis B virus (HBV) infection.
    J Hepatol. 2023 Jan 27:S0168-8278(23)00029-6. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    
66. MAGGIORE G, Bernard O, Mosca A, Ballot E, et al
    Long-term outcomes of patients with type 1 or 2 autoimmune hepatitis presenting in childhood.
    J Hepatol. 2023 Jan 25:S0168-8278(23)00025-9. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    
67. BURGER D, Aktas H, de Knegt R
    Sustained virological response in an HCV-infected patient on an enzyme-inducing anti-epileptic agent despite undetectable trough plasma levels of velpatasvir.
    J Hepatol. 2023 Jan 25:S0168-8278(23)00027-2. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    
68. LUCIFORA J, Alfaiate D, Pons C, Michelet M, et al
    Hepatitis D virus interferes with hepatitis B virus RNA production via interferon-dependent and -independent mechanisms.
    J Hepatol. 2023 Jan 23:S0168-8278(23)00016-8. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    
69. MAALEJ NH, Collins IJ, Ades AE, Scott K, et al
    Modelling the potential effectiveness of hepatitis C screening and treatment strategies during pregnancy in Egypt and Ukraine.
    J Hepatol. 2023 Jan 17:S0168-8278(23)00014-4. doi: 10.1016/j.jhep.2022.
    PubMed     Abstract available
    
    
    
70. SANDMANN L, Tergast TL, Wedemeyer H, Deterding K, et al
    3P and 5P model of limited value for the detection of clinically significant portal hypertension in patients with hepatitis delta.
    J Hepatol. 2023 Jan 17:S0168-8278(23)00010-7. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    December 2022
71. SU J, Brunner L, Oz EA, Sacherl J, et al
    Activation of CD4 T cells during prime immunization determines the success of a therapeutic hepatitis B vaccine in HBV-carrier mouse models.
    J Hepatol. 2022 Dec 30:S0168-8278(22)03465-1. doi: 10.1016/j.jhep.2022.
    PubMed     Abstract available
    
    
    
72. ADRANEDA C, Tan YC, Yeo EJ, Kew GS, et al
    A critique and systematic review of the clinical utility of hepatitis B core-related antigen.
    J Hepatol. 2022 Dec 28:S0168-8278(22)03469-9. doi: 10.1016/j.jhep.2022.
    PubMed     Abstract available
    
    
    
73. LEISKAU C, Tsaka S, Meyer-Ruhnke L, Mutschler FE, et al
    Acute severe non-A-E-hepatitis of unknown origin in children - a 30-year retrospective observational study from north-west Germany.
    J Hepatol. 2022 Dec 23:S0168-8278(22)03464-X. doi: 10.1016/j.jhep.2022.
    PubMed     Abstract available
    
    
    
74. CHOI WM, Cheuk-Fung Yip T, Lai-Hung Wong G, Kim WR, et al
    Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir-vs. entecavir-based regimens: individual patient data meta-analysis.
    J Hepatol. 2022 Dec 23:S0168-8278(22)03459-6. doi: 10.1016/j.jhep.2022.
    PubMed     Abstract available
    
    
    
75. SHEN Y, Liu Y, Yu K, Shen M, et al
    G-CSF exacerbates liver injury in a mouse model of autoimmune hepatitis.
    J Hepatol. 2022 Dec 16:S0168-8278(22)03414-6. doi: 10.1016/j.jhep.2022.
    PubMed    
    
    
    
76. SNIJDERS RJALM, Gevers TJG, Drenth JPH
    The value of surrogate endpoints and predictive markers in autoimmune hepatitis.
    J Hepatol. 2022 Dec 16:S0168-8278(22)03413-4. doi: 10.1016/j.jhep.2022.
    PubMed    
    
    
    
77. EUROPEAN ASSOCIATION FOR THE S
    Corrigendum to 'EASL recommendations on treatment of hepatitis C: Final update of the series(') [J Hepatol 73 (2020) 1170-1218].
    J Hepatol. 2022 Dec 1:S0168-8278(22)03142-7. doi: 10.1016/j.jhep.2022.
    PubMed    
    
    
    
78. YIP TC, Wong VW, Lai MS, Lai JC, et al
    Risk of hepatic decompensation but not hepatocellular carcinoma decreases over time in patients with hepatitis B surface antigen loss.
    J Hepatol. 2022 Dec 1:S0168-8278(22)03314-1. doi: 10.1016/j.jhep.2022.
    PubMed     Abstract available
    
    
    November 2022
79. VAN DER PLUIJM RW, Smits LP, Rebers SP, Schinkel J, et al
    Unmasking of a hepatitis c genotype 3a/1b dual infection in an individual treated with elbasvir/ grazoprevir.
    J Hepatol. 2022 Nov 23:S0168-8278(22)03310-4. doi: 10.1016/j.jhep.2022.
    PubMed    
    
    
    
80. CHOI J
    Reply to: Correspondence on "Impact of HBsAg seroclearance on late recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection".
    J Hepatol. 2022;77:1472-1474.
    PubMed    
    
    
    
81. YUEN MF, Locarnini S, Lim TH, Strasser SI, et al
    Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB.
    J Hepatol. 2022;77:1287-1298.
    PubMed     Abstract available
    
    
    October 2022
82. ENGEL B, Jaeckel E, Taubert R
    2022 International Autoimmune Hepatitis Group non-response criteria in autoimmune hepatitis: Quick vs. slow responders.
    J Hepatol. 2022 Oct 12. pii: S0168-8278(22)03138.
    PubMed    
    
    
    
83. TSAI PC, Kuo HT, Hung CH, Tseng KC, et al
    Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan.
    J Hepatol. 2022 Oct 5. pii: S0168-8278(22)03129.
    PubMed     Abstract available
    
    
    
84. AGARWAL K, Lok J, Gane E
    Antisense oligonucleotides (ASOs) in chronic hepatitis B infection: Opportunities and challenging the orthodoxy.
    J Hepatol. 2022;77:906-908.
    PubMed    
    
    
    
85. LEE SK, Kwon JH, Yoon N, Lee SH, et al
    Immune-mediated liver injury represented as overlap syndrome after SARS-CoV-2 vaccination.
    J Hepatol. 2022;77:1209-1211.
    PubMed    
    
    
    September 2022
86. CARSON JM, Barbieri S, Matthews GV, Dore GJ, et al
    National trends in retreatment of HCV due to reinfection or treatment failure in Australia.
    J Hepatol. 2022 Sep 21. pii: S0168-8278(22)03118.
    PubMed     Abstract available
    
    
    
87. GILLICH N, Zhang Z, Binder M, Urban S, et al
    Effect of variants in LGP2 on MDA5-mediated activation of interferon response and suppression of hepatitis D virus replication.
    J Hepatol. 2022 Sep 21. pii: S0168-8278(22)03113.
    PubMed     Abstract available
    
    
    
88. OLTMANNS C, Liu Z, Mischke J, Tauwaldt J, et al
    Reverse Inflammaging: Long-term effects of HCV cure on biological age.
    J Hepatol. 2022 Sep 21. pii: S0168-8278(22)03115.
    PubMed     Abstract available
    
    
    
89. SUN L, Feng H, Misumi I, Shirasaki T, et al
    Viral protease cleavage of MAVS in genetically modified mice with hepatitis A virus infection.
    J Hepatol. 2022 Sep 21. pii: S0168-8278(22)03120.
    PubMed     Abstract available
    
    
    
90. MARTIN-NAVARRO L, de Andrea C, Sangro B, Argemi J, et al
    In situ detection of vaccine mRNA in the cytoplasm of hepatocytes during COVID19 vaccine-related hepatitis.
    J Hepatol. 2022 Sep 15. pii: S0168-8278(22)03076.
    PubMed    
    
    
    
91. PEETERS M, Schenk J, De Somer T, Roskams T, et al
    Viral clade is associated with severity of symptomatic genotype 3 Hepatitis E virus infections in Belgium, 2010-2018.
    J Hepatol. 2022 Sep 5. pii: S0168-8278(22)03064.
    PubMed     Abstract available
    
    
    
92. YI H, Lin Y, Lu B, Mao Y, et al
    The origin of severe hepatitis of unknown aetiology in children: SARS-CoV-2 or adenovirus?
    J Hepatol. 2022 Sep 3. pii: S0168-8278(22)03063.
    PubMed    
    
    
    
93. SEMMLER G, Lens S, Meyer EL, Baiges A, et al
    Non-invasive tests for clinically significant portal hypertension after HCV cure.
    J Hepatol. 2022 Sep 2. pii: S0168-8278(22)03056.
    PubMed     Abstract available
    
    
    
94. CHO Y, Bukong TN, Tornai D, Babuta M, et al
    Neutrophil extracellular traps contribute to liver damage and increase defective low-density neutrophils in alcoholic hepatitis.
    J Hepatol. 2022 Sep 2. pii: S0168-8278(22)03060.
    PubMed     Abstract available
    
    
    
95. YANG H, Bae SH, Jang JW
    Reply to: 'A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: considerations'.
    J Hepatol. 2022 Sep 1. pii: S0168-8278(22)03057.
    PubMed    
    
    
    August 2022
96. WANG Q, Zhao H, Deng Y, Zheng H, et al
    Validation of Baveno VII criteria for recompensation in entecavir-treated individuals with hepatitis B-related decompensated cirrhosis.
    J Hepatol. 2022 Aug 26. pii: S0168-8278(22)03019.
    PubMed     Abstract available
    
    
    
97. DIETZ J, Mullhaupt B, Buggisch P, Graf C, et al
    Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure.
    J Hepatol. 2022 Aug 25. pii: S0168-8278(22)03016.
    PubMed     Abstract available
    
    
    
98. JI D, Chen Y, Bi J, Shang Q, et al
    Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B.
    J Hepatol. 2022 Aug 16. pii: S0168-8278(22)02982.
    PubMed     Abstract available
    
    
    
99. SNIJDERS RJALM, Gevers TJG, Heneghan MA, Drenth JPH, et al
    Defining endpoints that guide treatment in autoimmune hepatitis.
    J Hepatol. 2022 Aug 16. pii: S0168-8278(22)02991.
    PubMed    
    
    
    
100. BRUGGEMANN Y, Klohn M, Todt D
     The pivotal role of CD8+ T cells in hepatitis E virus infection.
     J Hepatol. 2022 Aug 14. pii: S0168-8278(22)02986.
     PubMed    
     
     
     
101. AGGARWAL A, Montanari NR, Ramirez R, Diehl L, et al
     Reply to: Hepatocyte expression of hepatitis B surface and core antigens across phases of chronic hepatitis B infection.
     J Hepatol. 2022 Aug 14. pii: S0168-8278(22)03000.
     PubMed    
     
     
     
102. DEGASPERI E, Anolli MP, Uceda Renteria SC, Sambarino D, et al
     Bulevirtide monotherapy for 48 Weeks in hdv patients with compensated cirrhosis and clinically significant portal hypertension.
     J Hepatol. 2022 Aug 13. pii: S0168-8278(22)02980.
     PubMed     Abstract available
     
     
     
103. JORGENSEN MH, Cananzi M, Buescher G, Samyn M, et al
     Children with autoimmune liver disease have limited access to age-appropriate drug formulations, results from a European survey.
     J Hepatol. 2022;77:551-553.
     PubMed    
     
     
     
104. WONG AM, Ding X, Wong AM, Xu M, et al
     Unique molecular characteristics of NAFLD-associated liver cancer accentuate beta-catenin/TNFRSF19-mediated immune evasion.
     J Hepatol. 2022;77:410-423.
     PubMed     Abstract available
     
     
     July 2022
105. LI Y, Xiao X, Miao Q, Ma X, et al
     Rapid response predicts complete biochemical response and histological remission in autoimmune hepatitis.
     J Hepatol. 2022 Jul 20. pii: S0168-8278(22)02945.
     PubMed    
     
     
     
106. SEMMLER G, Meyer EL, Mandorfer M
     De-novo-HCC risk stratification after HCV-cure: All roads lead to Rome?
     J Hepatol. 2022 Jul 19. pii: S0168-8278(22)02944.
     PubMed    
     
     
     
107. LIU SY, Yuan C, Tong XM
     Antiviral therapy, HBsAg seroclearance and late recurrence of Hepatitis B-related hepatocellular carcinoma.
     J Hepatol. 2022 Jul 18. pii: S0168-8278(22)02938.
     PubMed    
     
     
     
108. DANDRI M, Volmari A, Lutgehetmann M
     The hepatitis delta virus and chronic hepatitis D.
     J Hepatol. 2022 Jul 15. pii: S0168-8278(22)00337.
     PubMed    
     
     
     
109. PAPATHEODORIDIS GV, Lekakis V, Voulgaris T, Lampertico P, et al
     Hepatitis B Virus Reactivation Associated with New Classes of Immunosuppressants and Immunomodulators: A Systematic Review, Meta-analysis, and Expert Opinion.
     J Hepatol. 2022 Jul 15. pii: S0168-8278(22)02935.
     PubMed     Abstract available
     
     
     
110. BUTI M, Craxi A, Foster GR, Maticic M, et al
     Viral hepatitis Elimination: Towards a hepatitis free world.
     J Hepatol. 2022 Jul 13. pii: S0168-8278(22)02934.
     PubMed    
     
     
     
111. VAN LEEUWEN LPM, de Jong W, Doornekamp L, van Gorp ECM, et al
     Exotic viral hepatitis; a review on epidemiology, pathogenesis, and treatment.
     J Hepatol. 2022 Jul 8. pii: S0168-8278(22)02930.
     PubMed     Abstract available
     
     
     
112. DI DATO F, Di Giorgio A, Mandato C, Maggiore G, et al
     Italian children seem to be spared from the mysterious severe acute hepatitis outbreak: a report by SIGENP Acute Hepatitis Group.
     J Hepatol. 2022 Jul 6. pii: S0168-8278(22)02924.
     PubMed    
     
     
     
113. KARIMI-SARI H, Rezaee-Zavareh MS, Falade-Nwulia O, Lim JK, et al
     Non-responders to sofosbuvir/velpatasvir/voxilaprevir in the treatment of chronic hepatitis C infection.
     J Hepatol. 2022 Jul 4. pii: S0168-8278(22)02922.
     PubMed    
     
     
     
114. AGARWAL K, Lok J, Carey I, Shivkar Y, et al
     A case of HBV-induced liver failure in the REEF-2 phase II trial: Implications for finite treatment strategies in HBV 'cure'.
     J Hepatol. 2022;77:245-248.
     PubMed     Abstract available
     
     
     
115. LAI MW, Chang YL, Cheng PJ, Chueh HY, et al
     Absence of chronicity in infants born to immunized mothers with occult HBV infection in Taiwan.
     J Hepatol. 2022;77:63-70.
     PubMed     Abstract available
     
     
     
116. HUANG D, Wu D, Wang P, Wang Y, et al
     End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB.
     J Hepatol. 2022;77:42-54.
     PubMed     Abstract available
     
     
     June 2022
117. LAMPERTICO P, Roulot D, Wedemeyer H
     BULEVIRTIDE WITH OR WITHOUT PEGIFNalpha FOR PATIENTS WITH COMPENSATED CHRONIC HEPATITIS DELTA: FROM CLINICAL TRIALS TO REAL LIFE STUDIES.
     J Hepatol. 2022 Jun 22. pii: S0168-8278(22)00373.
     PubMed     Abstract available
     
     
     
118. HOOGEVEEN RC, Dijkstra S, Bartsch LM, Drescher H, et al
     Hepatitis B virus-specific CD4 T-cell responses differentiate functional cure from chronic surface antigen(+) infection.
     J Hepatol. 2022 Jun 15. pii: S0168-8278(22)00366.
     PubMed     Abstract available
     
     
     
119. MEDAS R, Liberal R, Cardoso H, Macedo G, et al
     2022 International Autoimmune Hepatitis Group non-response criteria in autoimmune hepatitis: a too early endpoint?
     J Hepatol. 2022 Jun 15. pii: S0168-8278(22)00367.
     PubMed    
     
     
     
120. YUEN MF, Heo J, Kumada H, Suzuki F, et al
     Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy.
     J Hepatol. 2022 Jun 14. pii: S0168-8278(22)00351.
     PubMed     Abstract available
     
     
     
121. LURZ E, Lenz D, Bufler P, Fichtner A, et al
     Letter to the editor - A peditatric hepatologists' perspective.
     J Hepatol. 2022 Jun 14. pii: S0168-8278(22)00363.
     PubMed    
     
     
     
122. SULKOWSKI MS, Agarwal K, Ma X, Nguyen TT, et al
     Safety and efficacy of vebicorvir administered with entecavir in treatment-naive patients with chronic hepatitis B virus infection.
     J Hepatol. 2022 Jun 10. pii: S0168-8278(22)00348.
     PubMed     Abstract available
     
     
     
123. TANG Y, Chen Y, Chen HN
     A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: considerations.
     J Hepatol. 2022 Jun 8. pii: S0168-8278(22)00354.
     PubMed    
     
     
     
124. SZABO G, Thursz M, Shah VH
     Therapeutic advances in alcohol-associated hepatitis.
     J Hepatol. 2022;76:1279-1290.
     PubMed     Abstract available
     
     
     
125. WONG GLH, Gane E, Lok ASF
     How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development?
     J Hepatol. 2022;76:1249-1262.
     PubMed     Abstract available
     
     
     May 2022
126. ZHANG Z, Ni Y, Lempp FA, Walter L, et al
     Hepatitis D virus-induced interferon response and administered interferons control cell division-mediated virus spread.
     J Hepatol. 2022 May 27. pii: S0168-8278(22)00338.
     PubMed     Abstract available
     
     
     
127. KEMMING J, Gundlach S, Panning M, Huzly D, et al
     Mechanisms of CD8+ T cell failure in chronic hepatitis E virus infection.
     J Hepatol. 2022 May 27. pii: S0168-8278(22)00334.
     PubMed     Abstract available
     
     
     
128. ZENG G, Huang J
     The recent outbreak of acute severe hepatitis in children of unknown origin.
     J Hepatol. 2022 May 26. pii: S0168-8278(22)00332.
     PubMed    
     
     
     
129. YOO S, Kim JY, Lim YS, Han S, et al
     Impact of HBsAg seroclearance on late recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection.
     J Hepatol. 2022 May 25. pii: S0168-8278(22)00329.
     PubMed     Abstract available
     
     
     
130. QIAN Z, Hao X, Xia Y, Yu W, et al
     Rat Hepatitis E virus is a potential zoonotic pathogen to humans.
     J Hepatol. 2022 May 25. pii: S0168-8278(22)00327.
     PubMed    
     
     
     
131. KUSHNER T, Djerboua M, Biondi MJ, Feld JJ, et al
     Influence of hepatitis C viral parameters on pregnancy complications and risk of mother-to-child transmission.
     J Hepatol. 2022 May 25. pii: S0168-8278(22)00331.
     PubMed     Abstract available
     
     
     
132. CHU CM, Liaw YF
     Hepatocyte expression of hepatitis B surface and core antigens across phases of chronic hepatitis B infection.
     J Hepatol. 2022 May 20. pii: S0168-8278(22)00324.
     PubMed    
     
     
     
133. MA Z, de Man RA, Kamar N, Pan Q, et al
     Chronic hepatitis E: advancing research and patient care.
     J Hepatol. 2022 May 20. pii: S0168-8278(22)00319.
     PubMed     Abstract available
     
     
     
134. SEUNG KJ, Franke MF, Hewison C, Huerga H, et al
     Corrigendum to 'High prevalence of hepatitis C infection among multidrug-resistant tuberculosis patients' [J Hepatol 72 (2020) 1028-1029].
     J Hepatol. 2022 May 14. pii: S0168-8278(22)00247.
     PubMed    
     
     
     
135. YEUNG A, Palmateer NE, Dillon JF, McDonald SA, et al
     Corrigendum to 'Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs' [J Hepatol 76 (2022) 549-557].
     J Hepatol. 2022 May 9. pii: S0168-8278(22)00248.
     PubMed    
     
     
     
136. MUCKE MM, Zeuzem S
     The recent outbreak of acute severe hepatitis in children of unknown origin - what is known so far.
     J Hepatol. 2022 May 6. pii: S0168-8278(22)00271.
     PubMed     Abstract available
     
     
     
137. SEMMLER G, Mandorfer M
     Substantiating evidence for HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease.
     J Hepatol. 2022 May 5. pii: S0168-8278(22)00267.
     PubMed    
     
     
     
138. BHAGAT N, Verma N, Singh V
     HCC prediction post SVR in HCV patients: many tools yet limited generalizability!
     J Hepatol. 2022 May 5. pii: S0168-8278(22)00264.
     PubMed    
     
     
     
139. LEMON SM
     Hepatitis A: Current view of an ancient disease.
     J Hepatol. 2022 May 2. pii: S0168-8278(21)02091.
     PubMed    
     
     
     
140. SONNEVELD MJ, Chiu SM, Park JY, Brakenhoff SM, et al
     Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels.
     J Hepatol. 2022;76:1042-1050.
     PubMed     Abstract available
     
     
     April 2022
141. BAYLIS SA, O'Flaherty N, Burke L, Hogema B, et al
     Identification of rabbit hepatitis E virus (HEV) and novel HEV clade in Irish blood donors.
     J Hepatol. 2022 Apr 26. pii: S0168-8278(22)00250.
     PubMed    
     
     
     
142. TIAN F, Feld JJ, Feng Z, Sander B, et al
     Feasibility of hepatitis B elimination in high-income countries with ongoing immigration.
     J Hepatol. 2022 Apr 25. pii: S0168-8278(22)00249.
     PubMed     Abstract available
     
     
     
143. BOETTLER T, Csernalabics B, Salie H, Luxenburger H, et al
     SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis.
     J Hepatol. 2022 Apr 21. pii: S0168-8278(22)00234.
     PubMed     Abstract available
     
     
     
144. YUEN MF, Agarwal K, Ma X, Nguyen TT, et al
     Efficacy and safety of vebicorvir administered in virologically-suppressed patients with chronic hepatitis B virus infection.
     J Hepatol. 2022 Apr 20. pii: S0168-8278(22)00238.
     PubMed     Abstract available
     
     
     
145. MAUNG NC, Liew ZHS, Leow WQ, Yeong PSJ, et al
     Severe de novo liver injury after Moderna vaccination - not always autoimmune hepatitis.
     J Hepatol. 2022 Apr 16. pii: S0168-8278(22)00236.
     PubMed    
     
     
     
146. YANG H, Bae SH, Nam H, Lee HL, et al
     A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
     J Hepatol. 2022 Apr 7. pii: S0168-8278(22)00208.
     PubMed     Abstract available
     
     
     
147. FRASER DA, Wang X, Lund J, Nikolic N, et al
     A structurally engineered fatty acid, icosabutate, suppresses liver inflammation and fibrosis in NASH.
     J Hepatol. 2022;76:800-811.
     PubMed     Abstract available
     
     
     March 2022
148. NAKATSUKA T, Tateishi R, Nakagomi R, Minami T, et al
     Risk stratification of hepatocellular carcinoma after hepatitis C virus eradication in patients with compensated advanced chronic liver disease in Japan.
     J Hepatol. 2022 Mar 11. pii: S0168-8278(22)00138.
     PubMed    
     
     
     
149. TORGERSEN J, Taddei TH, Lo Re V 3rd
     Reply to: "Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with PI-based DAA?"
     J Hepatol. 2022 Mar 10. pii: S0168-8278(22)00132.
     PubMed    
     
     
     
150. RUTHER DF, Weltzsch JP, Schramm C, Sebode M, et al
     Autoimmune hepatitis and COVID-19: No increased risk for AIH after vaccination but reduced care.
     J Hepatol. 2022 Mar 10. pii: S0168-8278(22)00120.
     PubMed    
     
     
     
151. GEHRING AJ, Mendez P, Richter K, Ertl H, et al
     Immunological Biomarker Discovery in Cure Regimens for Chronic Hepatitis B Virus Infection.
     J Hepatol. 2022 Mar 5. pii: S0168-8278(22)00127.
     PubMed     Abstract available
     
     
     February 2022
152. MONTANARI NR, Ramirez R, Aggarwal A, van Buuren N, et al
     Multi-parametric analysis of human livers reveals variation in intrahepatic inflammation across phases of chronic hepatitis B infection.
     J Hepatol. 2022 Feb 23. pii: S0168-8278(22)00123.
     PubMed     Abstract available
     
     
     
153. RIVERO-JUAREZ A, Frias M, Perez AB, Pineda JA, et al
     Orthohepevirus C infection as an emerging cause of acute hepatitis in Spain: first report in Europe.
     J Hepatol. 2022 Feb 12. pii: S0168-8278(22)00075.
     PubMed     Abstract available
     
     
     
154. MUELLER PP, Chen Q, Ayer T, Nemutlu G, et al
     Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication.
     J Hepatol. 2022 Feb 11. pii: S0168-8278(22)00074.
     PubMed     Abstract available
     
     
     
155. LESLIE J, Geh D, Elsharkawy AM, Mann DA, et al
     Metabolic dysfunction and cancer in HCV: shared pathways and mutual interactions.
     J Hepatol. 2022 Feb 11. pii: S0168-8278(22)00076.
     PubMed     Abstract available
     
     
     
156. MONTANO-LOZA AJ, Ronca V, Ebadi M, Hansen BE, et al
     Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation.
     J Hepatol. 2022 Feb 7. pii: S0168-8278(22)00067.
     PubMed     Abstract available
     
     
     
157. JACHS M, Scheiner B, Pinter M
     Letter to the editor: Immunotherapy for hepatocellular carcinoma in a patient with hepatitis B virus and hepatitis delta virus coinfection.
     J Hepatol. 2022 Feb 3. pii: S0168-8278(22)00030.
     PubMed    
     
     
     January 2022
158. BEHRENDT P, Friesland M, Wissmann JE, Kinast V, et al
     Hepatitis E virus is highly resistant to alcohol-based disinfectants.
     J Hepatol. 2022 Jan 24. pii: S0168-8278(22)00019.
     PubMed     Abstract available
     
     
     
159. GALLARD C, Lebsir N, Khursheed H, Reungoat E, et al
     Heparanase is upregulated by HCV and favors its replication.
     J Hepatol. 2022 Jan 24. pii: S0168-8278(22)00021.
     PubMed     Abstract available
     
     
     
160. WONG YJ, Nguyen MH
     Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with PI-based DAA?
     J Hepatol. 2022 Jan 21. pii: S0168-8278(22)00008.
     PubMed    
     
     
     
161. PAPE S, Snijders RJ, Gevers TJ, Chazouilleres O, et al
     Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group.
     J Hepatol. 2022 Jan 20. pii: S0168-8278(22)00012.
     PubMed     Abstract available
     
     
     
162. SHEKHTMAN L, Cotler SJ, Ploss A, Dahari H, et al
     Mathematical modeling suggests that entry-inhibitor Bulevirtide may interfere with hepatitis D virus clearance from circulation.
     J Hepatol. 2022 Jan 4. pii: S0168-8278(21)02307.
     PubMed    
     
     
     
163. PIHL AF, Feng S, Offersgaard A, Alzua GP, et al
     Inactivated whole hepatitis C virus vaccine employing a licensed adjuvant elicits cross-genotype neutralizing antibodies in mice.
     J Hepatol. 2022 Jan 3. pii: S0168-8278(21)02303.
     PubMed     Abstract available
     
     
     December 2021
164. BEAUMONT E, Larochette V, Preisser L, Miot C, et al
     IL-26 inhibits hepatitis C virus replication in hepatocytes.
     J Hepatol. 2021 Dec 21. pii: S0168-8278(21)02253.
     PubMed     Abstract available
     
     
     
165. SEMMLER G, Meyer EL, Kozbial K, Schwabl P, et al
     HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease.
     J Hepatol. 2021 Dec 3. pii: S0168-8278(21)02234.
     PubMed     Abstract available
     
     
     
166. ZHANG M, Zhang Z, Imamura M, Osawa M, et al
     Infection courses, virological features and IFN-alpha responses of HBV genotypes in cell culture and animal models.
     J Hepatol. 2021;75:1335-1345.
     PubMed     Abstract available
     
     
     November 2021
167. SANDUZZI-ZAMPARELLI M, Marino Z, Lens S, Sapena V, et al
     Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules.
     J Hepatol. 2021 Nov 29. pii: S0168-8278(21)02228.
     PubMed     Abstract available
     
     
     
168. DE MARTIN E, Duclos-Vallee JC
     Reply to "validation of the SURFASA score to define steroid responsiveness in patients with acute autoimmune hepatitis".
     J Hepatol. 2021 Nov 10. pii: S0168-8278(21)02167.
     PubMed    
     
     
     
169. TENG Y, Xu Z, Zhao K, Zhong Y, et al
     Novel function of SART1 in HNF4alpha transcriptional regulation contributes to its antiviral role during HBV infection.
     J Hepatol. 2021;75:1072-1082.
     PubMed     Abstract available
     
     
     October 2021
170. LOGLIO A, Ferenci P, Uceda Renteria SC, Tham CYL, et al
     Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosis.
     J Hepatol. 2021 Oct 23. pii: S0168-8278(21)02119.
     PubMed     Abstract available
     
     
     
171. YUAN S, Yang Y, Hu R
     The Unfolding Multiomics Landscapes of HBV (Hepatitis B Virus)-Host Interactions.
     J Hepatol. 2021 Oct 11. pii: S0168-8278(21)02101.
     PubMed    
     
     
     
172. YEUNG A, Palmateer NE, Dillon JF, McDonald SA, et al
     Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs.
     J Hepatol. 2021 Oct 8. pii: S0168-8278(21)02103.
     PubMed     Abstract available
     
     
     
173. TUN GS, Gleeson D, Dube A, Al-Joudeh A, et al
     Immune-mediated hepatitis with the Moderna vaccine, no longer a coincidence but confirmed.
     J Hepatol. 2021 Oct 4. pii: S0168-8278(21)02093.
     PubMed    
     
     
     
174. KIM HY, Lampertico P, Nam JY, Lee HC, et al
     An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B.
     J Hepatol. 2021 Oct 1. pii: S0168-8278(21)02087.
     PubMed     Abstract available
     
     
     
175. MALLET V, Beeker N, Bouam S, Sogni P, et al
     Prognosis of French COVID-19 patients with chronic liver disease: A national retrospective cohort study for 2020.
     J Hepatol. 2021;75:848-855.
     PubMed     Abstract available
     
     
     
176. WANG GP, Schnell GL, Kort JJ, Sidhu GS, et al
     Linkage of resistance-associated substitutions in GT1 sofosbuvir + NS5A inhibitor failures treated with glecaprevir/pibrentasvir.
     J Hepatol. 2021;75:820-828.
     PubMed     Abstract available
     
     
     
177. MEIER MA, Calabrese D, Suslov A, Terracciano LM, et al
     Ubiquitous expression of HBsAg from integrated HBV DNA in patients with low viral load.
     J Hepatol. 2021;75:840-847.
     PubMed     Abstract available
     
     
     September 2021
178. CACOUB P, Comarmond C, Vieira M, Regnier P, et al
     HCV-related lymphoproliferative disorders in the direct-acting antivirals era: from mixed cryoglobulinemia to B-cell lymphoma.
     J Hepatol. 2021 Sep 29. pii: S0168-8278(21)02084.
     PubMed     Abstract available
     
     
     
179. RAHIM MN, Heneghan MA
     Reply to "The Search for Optimum Thiopurine Metabolite Levels in Autoimmune Hepatitis Continues".
     J Hepatol. 2021 Sep 27. pii: S0168-8278(21)02046.
     PubMed    
     
     
     
180. D'AMBROSIO R, Degasperi E, Anolli MP, Fanetti I, et al
     Incidence of liver and non-liver-related outcomes in patients with HCV-cirrhosis after SVR.
     J Hepatol. 2021 Sep 27. pii: S0168-8278(21)02043.
     PubMed     Abstract available
     
     
     
181. CHOI WM, Yip TC, Lim YS, Wong GL, et al
     Methodological Challenges in Meta-Analysis to Assess the Risk of Hepatocellular Carcinoma Across Chronic Hepatitis B Treatments.
     J Hepatol. 2021 Sep 27. pii: S0168-8278(21)02079.
     PubMed     Abstract available
     
     
     
182. KIM HS, Yu X, Kramer J, Thrift AP, et al
     Comparative performance of risk prediction models for hepatitis B-related hepatocellular carcinoma in the United States.
     J Hepatol. 2021 Sep 23. pii: S0168-8278(21)02039.
     PubMed     Abstract available
     
     
     
183. MALLET V, Scarano Pereira JP, Martinino A, Roque-Afonso AM, et al
     The rise of the hepatitis E virus.
     J Hepatol. 2021 Sep 16. pii: S0168-8278(21)00303.
     PubMed    
     
     
     
184. LACKNER C, Stauber RE, Tiniakos D
     Reply to: Prognostic value of histologic parameters in alcoholic hepatitis: a word of caution.
     J Hepatol. 2021 Sep 16. pii: S0168-8278(21)02035.
     PubMed    
     
     
     
185. GAO Y, You M, Fu J, Tian M, et al
     Intratumoral stem-like CCR4+ regulatory T cells orchestrate the immunosuppressive microenvironment in HCC associated with hepatitis B.
     J Hepatol. 2021 Sep 12. pii: S0168-8278(21)02027.
     PubMed     Abstract available
     
     
     August 2021
186. YE Q, Kam LY, Yeo YH, Dang N, et al
     Substantial gaps in evaluation and treatment of patients with hepatitis B in the US.
     J Hepatol. 2021 Aug 30. pii: S0168-8278(21)02014.
     PubMed     Abstract available
     
     
     
187. CORDES AK, Goudeva L, Lutgehetmann M, Wenzel JJ, et al
     Risk of transfusion-transmitted hepatitis E virus infection from pool-tested platelets and plasma.
     J Hepatol. 2021 Aug 27. pii: S0168-8278(21)02013.
     PubMed     Abstract available
     
     
     
188. LIN S, Hall A, Kumar R, Quaglia A, et al
     Validation of the SURFASA score to define steroid responsiveness in patients with acute autoimmune hepatitis.
     J Hepatol. 2021 Aug 25. pii: S0168-8278(21)02008.
     PubMed    
     
     
     
189. ZHOU T, Fronhoffs F, Dold L, Strassburg CP, et al
     New-Onset Autoimmune Hepatitis following mRNA Covid-19 Vaccination in a 36-year-old woman with Primary Sclerosing Cholangitis - should we be more vigilant?
     J Hepatol. 2021 Aug 24. pii: S0168-8278(21)02000.
     PubMed    
     
     
     
190. DO CARMO RF, de Souza CDF
     Impact of the COVID-19 pandemic on hepatitis C diagnosis in Brazil: Is the global hepatitis C elimination strategy at risk?
     J Hepatol. 2021 Aug 23. pii: S0168-8278(21)01999.
     PubMed    
     
     
     
191. FERNANDO B
     Autoimmune Hepatitis Developing After Coronavirus Disease 2019 (COVID-19) Vaccine: One or Even Several Swallows Do Not Make a Summer.
     J Hepatol. 2021 Aug 9. pii: S0168-8278(21)01965.
     PubMed    
     
     
     
192. XU H, Locarnini S, Wong D, Hammond R, et al
     Role of anti-HBs in functional cure of HBeAg+ chronic hepatitis B patients infected with HBV genotype A.
     J Hepatol. 2021 Aug 6. pii: S0168-8278(21)01959.
     PubMed     Abstract available
     
     
     July 2021
193. MISUMI I, Mitchell JE, Lund MM, Cullen JM, et al
     T cells protect against hepatitis A virus infection and limit infection-induced liver injury.
     J Hepatol. 2021 Jul 28. pii: S0168-8278(21)01949.
     PubMed     Abstract available
     
     
     
194. DELTENRE P, Marot A
     Prognostic value of histologic parameters in alcoholic hepatitis: a word of caution.
     J Hepatol. 2021 Jul 20. pii: S0168-8278(21)01912.
     PubMed    
     
     
     
195. BORGIA SM, Shafran SD
     Reply to: "Real-world experience of serial serum levels of GS-331007 in chronic hepatitis C hemodialysis patients during and after sofosbuvir/velpatasvir therapy".
     J Hepatol. 2021 Jul 19. pii: S0168-8278(21)01908.
     PubMed    
     
     
     
196. KIRCHNER T, Jaeckel E, Falk CS, Eiz-Vesper B, et al
     SARS-CoV-2-specific immunity in immunosuppressed COVID-19 convalescents with autoimmune hepatitis.
     J Hepatol. 2021 Jul 17. pii: S0168-8278(21)01911.
     PubMed    
     
     
     
197. MONTALDO C, Terri M, Riccioni V, Battistelli C, et al
     Fibrogenic signals persist in DAA-treated HCV patients after sustained virological response.
     J Hepatol. 2021 Jul 13. pii: S0168-8278(21)01901.
     PubMed     Abstract available
     
     
     
198. LODATO F, Larocca A, D'Errico A, Cennamo V, et al
     AN ANUSUAL CASE OF ACUTE CHOLESTATIC HEPATITIS AFTER m-RNABNT162b2 (COMIRNATY) SARS-CoV-2 VACCINE: COINCIDENCE, AUTOIMMUNITY OR DRUG RELATED LIVER INJURY?
     J Hepatol. 2021 Jul 10. pii: S0168-8278(21)01904.
     PubMed    
     
     
     
199. MCSHANE C, Kiat C, Rigby J, Crosbie O, et al
     The mRNA COVID-19 vaccine - a rare trigger of Autoimmune Hepatitis?
     J Hepatol. 2021 Jul 7. pii: S0168-8278(21)01896.
     PubMed    
     
     
     
200. LLEWELLYN HP, Arat S, Gao J, Wen J, et al
     T cells and monocyte-derived myeloid cells mediate immunotherapy-related hepatitis in a mouse model.
     J Hepatol. 2021 Jul 6. pii: S0168-8278(21)01887.
     PubMed     Abstract available
     
     
     
201. BOLIA R, Srivastava A
     The Search For Optimum Thiopurine Metabolite Levels in Autoimmune Hepatitis Continues....
     J Hepatol. 2021 Jul 6. pii: S0168-8278(21)01890.
     PubMed    
     
     
     
202. GRANITO A, Muratori P, Muratori L
     Acute-on-chronic liver failure: a complex clinical entity in patients with autoimmune hepatitis.
     J Hepatol. 2021 Jul 3. pii: S0168-8278(21)01884.
     PubMed    
     
     
     
203. YUAN S, Liao G, Zhang M, Zhu Y, et al
     Translatomic profiling reveals novel self-restricting virus-host interactions during HBV infection.
     J Hepatol. 2021;75:74-85.
     PubMed     Abstract available
     
     
     June 2021
204. PAPATHEODORIDI M, Papatheodoridis G
     New concepts in the finite oral antiviral therapy in HBeAg-negative chronic hepatitis B.
     J Hepatol. 2021 Jun 22. pii: S0168-8278(21)00440.
     PubMed    
     
     
     
205. CLAYTON-CHUBB D, Schneider D, Freeman E, Kemp W, et al
     Comment to the letter of Bril F et al. "Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty?"
     J Hepatol. 2021 Jun 22. pii: S0168-8278(21)00427.
     PubMed    
     
     
     
206. QUITT O, Luo S, Meyer M, Xie Z, et al
     T-cell engager antibodies enable T cells to control HBV infection and to target HBsAg-positive hepatoma in mice.
     J Hepatol. 2021 Jun 22. pii: S0168-8278(21)00443.
     PubMed     Abstract available
     
     
     
207. ARAB JP, Diaz LA, Baeza N, Idalsoaga F, et al
     IDENTIFICATION OF OPTIMAL THERAPEUTIC WINDOW FOR STEROID USE IN SEVERE ALCOHOL-ASSOCIATED HEPATITIS: A WORLDWIDE STUDY.
     J Hepatol. 2021 Jun 21. pii: S0168-8278(21)00439.
     PubMed     Abstract available
     
     
     
208. TAN CK, Wong YJ, Wang LM, Ang TL, et al
     Autoimmune hepatitis following COVID-19 Vaccination: true causality or mere association?
     J Hepatol. 2021 Jun 18. pii: S0168-8278(21)00424.
     PubMed    
     
     
     
209. BRIL F, Fettig DM
     Response to letter to the editor by Capecchi et al. "Comment to the letter of Bril F et al. "Autoimmune Hepatitis Developing After Coronavirus Disease 2019 (COVID-19) Vaccine: Causality or Casualty?"
     J Hepatol. 2021 Jun 16. pii: S0168-8278(21)00423.
     PubMed    
     
     
     
210. BOU SALEH M, Louvet A, Ntandja-Wandji LC, Boleslawski E, et al
     Loss of hepatocyte identity following aberrant YAP activation: a key mechanism in alcoholic hepatitis.
     J Hepatol. 2021 Jun 12. pii: S0168-8278(21)00416.
     PubMed     Abstract available
     
     
     
211. LONDONO MC, Gratacos-Gines J, Saez-Penataro J
     Another case of autoimmune hepatitis after SARS-CoV-2 vaccination. Still casualty?
     J Hepatol. 2021 Jun 12. pii: S0168-8278(21)00417.
     PubMed    
     
     
     
212. MARCOS-FOSCH C, Cabezas J, Crespo J, Buti M, et al
     Anti-epileptic drugs and hepatitis C therapy: real world experience.
     J Hepatol. 2021 Jun 11. pii: S0168-8278(21)00414.
     PubMed    
     
     
     
213. ROCCO A, Sgamato C, Compare D, Nardone G, et al
     Autoimmune hepatitis following sars-cov-2 VACCINE: MAY not be a casualty.
     J Hepatol. 2021 Jun 8. pii: S0168-8278(21)00412.
     PubMed    
     
     
     
214. JANJUA NZ, Wong S, Abdia Y, Jeong D, et al
     Impact of direct-acting antivirals for HCV on mortality in a large population-based cohort study.
     J Hepatol. 2021 Jun 4. pii: S0168-8278(21)00401.
     PubMed     Abstract available
     
     
     
215. LI J, Liang X, You S, Feng T, et al
     Development and validation of a new prognostic score for hepatitis B virus-related acute-on-chronic liver failure.
     J Hepatol. 2021 Jun 3. pii: S0168-8278(21)00399.
     PubMed     Abstract available
     
     
     
216. DING ZY, Li GX, Chen L, Shu C, et al
     Association of liver abnormalities with in-hospital mortality in patients with COVID-19.
     J Hepatol. 2021;74:1295-1302.
     PubMed     Abstract available
     
     
     
217. SARRAZIN C
     Treatment failure with DAA therapy: Importance of resistance.
     J Hepatol. 2021;74:1472-1482.
     PubMed     Abstract available
     
     
     
218. CHEN J, Liu B, Tang X, Zheng X, et al
     Role of core protein mutations in the development of occult HBV infection.
     J Hepatol. 2021;74:1303-1314.
     PubMed     Abstract available
     
     
     May 2021
219. MATHURIN P
     Early liver transplantation for acute alcoholic hepatitis: we can't say no.
     J Hepatol. 2021 May 28. pii: S0168-8278(21)00354.
     PubMed     Abstract available
     
     
     
220. KOLAMUNNAGE-DONA R, Berhane S, Potts H, Williams EH, et al
     Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma.
     J Hepatol. 2021 May 27. pii: S0168-8278(21)00350.
     PubMed     Abstract available
     
     
     
221. HUANG CF, Wei YJ, Wu YT, Chiu YW, et al
     Real world experience of serial serum levels of GS-331007 in chronic hepatitis C hemodialysis patients during and after sofosbuvir/velpatasvir therapy.
     J Hepatol. 2021 May 26. pii: S0168-8278(21)00351.
     PubMed    
     
     
     
222. MARTINEZ MG, Boyd A, Combe E, Testoni B, et al
     Covalently closed circular DNA: the ultimate therapeutic target for curing Hepatitis B virus infections.
     J Hepatol. 2021 May 26. pii: S0168-8278(21)00348.
     PubMed     Abstract available
     
     
     
223. DE MARTIN E, Duclos-Vallee JC
     Reply to "Acute severe autoimmune hepatitis - timing for steroids and role of other immunosuppressive agents".
     J Hepatol. 2021 May 26. pii: S0168-8278(21)00345.
     PubMed    
     
     
     
224. MATTHEWS GV, Bhagani S, Van der Valk M, Rockstroh J, et al
     Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection.
     J Hepatol. 2021 May 20. pii: S0168-8278(21)00336.
     PubMed     Abstract available
     
     
     
225. RODRIGUES PM, Olaizola P, Banales JM
     Unscrambling a novel pathogenic role for interleukin-20 in acute hepatitis and bacterial infection: A double-edged sword?
     J Hepatol. 2021 May 10. pii: S0168-8278(21)00183.
     PubMed    
     
     
     
226. SHAH R, Ahovegbe L, Niebel M, Shepherd J, et al
     Non-epidemic HCV genotypes in low- and middle-income countries and the risk of resistance to current direct-acting antiviral regimens.
     J Hepatol. 2021 May 8. pii: S0168-8278(21)00310.
     PubMed     Abstract available
     
     
     
227. CRESPO J, Diaz-Gonzalez A, Cabezas J
     HCV detection is possible during SARS CoV-2 testing; and throughout COVID-19 vaccination?
     J Hepatol. 2021 May 7. pii: S0168-8278(21)00308.
     PubMed    
     
     
     
228. CAPECCHI PL, Lazzerini PE, Brillanti S
     Comment to the letter of Bril F et al. "Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) Vaccine: Causality or casualty?"
     J Hepatol. 2021 May 5. pii: S0168-8278(21)00304.
     PubMed    
     
     
     
229. ZENG DY, Li JM, Lin S, Dong X, et al
     Global burden of acute viral hepatitis and its association with socioeconomic development status, 1990-2019.
     J Hepatol. 2021 May 4. pii: S0168-8278(21)00300.
     PubMed     Abstract available
     
     
     
230. BREMER W, Blasczyk H, Yin X, Duron ES, et al
     Resolution of hepatitis E virus infection in CD8+ T cell depleted rhesus macaques.
     J Hepatol. 2021 May 4. pii: S0168-8278(21)00301.
     PubMed     Abstract available
     
     
     
231. REIG M, Cabibbo G
     Antiviral therapy in the palliative setting of HCC (BCLC-B and -C).
     J Hepatol. 2021;74:1225-1233.
     PubMed     Abstract available
     
     
     
232. HIGASHI-KUWATA N, Hayashi S, Kumamoto H, Ogata-Aoki H, et al
     Identification of a novel long-acting 4'-modified nucleoside reverse transcriptase inhibitor against HBV.
     J Hepatol. 2021;74:1075-1086.
     PubMed     Abstract available
     
     
     
233. PAPATHEODORIDI M, Hiriart JB, Lupsor-Platon M, Bronte F, et al
     Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease.
     J Hepatol. 2021;74:1109-1116.
     PubMed     Abstract available
     
     
     April 2021
234. LIBERAL R, Macedo G
     Acute severe autoimmune hepatitis - timing for steroids and role of other immunosuppressive agents.
     J Hepatol. 2021 Apr 29. pii: S0168-8278(21)00297.
     PubMed    
     
     
     
235. DIETZ J, Sarrazin C
     Reply to "glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings".
     J Hepatol. 2021 Apr 20. pii: S0168-8278(21)00252.
     PubMed    
     
     
     
236. LLAMOSAS-FALCON L, Shield KD, Gelovany M, Hasan OSM, et al
     Impact of alcohol on the progression of HCV-related liver disease: A systematic review and meta-analysis.
     J Hepatol. 2021 Apr 20. pii: S0168-8278(21)00253.
     PubMed     Abstract available
     
     
     
237. SONNEVELD MJ, Veldhuijzen IK, van de Laar T, Op de Coul ELM, et al
     DECREASE IN VIRAL HEPATITIS DIAGNOSES DURING THE COVID-19 PANDEMIC IN THE NETHERLANDS.
     J Hepatol. 2021 Apr 19. pii: S0168-8278(21)00250.
     PubMed    
     
     
     
238. CANDELS LS, Rahim MN, Shah S, Heneghan MA, et al
     Towards personalised medicine in autoimmune hepatitis: Measurement of thiopurine metabolites results in higher biochemical response rates compared to standard weight-based dosing of thiopurine therapy.
     J Hepatol. 2021 Apr 16. pii: S0168-8278(21)00227.
     PubMed     Abstract available
     
     
     
239. BRIL F, Al Diffalha S, Dean M, Fettig DM, et al
     Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) Vaccine: Causality or casualty?
     J Hepatol. 2021 Apr 13. pii: S0168-8278(21)00237.
     PubMed    
     
     
     
240. WANG W, Lempp FA, Schlund F, Walter L, et al
     Assembly and infection efficacy of hepatitis B virus surface protein exchanges in eight hepatitis D virus genotype isolates.
     J Hepatol. 2021 Apr 9. pii: S0168-8278(21)00229.
     PubMed     Abstract available
     
     
     
241. GERLICH W
     Hepatitis B virus - an anaerobic organism?
     J Hepatol. 2021 Apr 2. pii: S0168-8278(21)00166.
     PubMed    
     
     
     
242. DIETZ J, Di Maio VC, de Salazar A, Merino D, et al
     Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy.
     J Hepatol. 2021;74:801-810.
     PubMed     Abstract available
     
     
     March 2021
243. LIAO SH, Chen CL, Hsu CY, Chien KL, et al
     Long-term Effectiveness of Population-wide Multifaceted Interventions for Hepatocellular Carcinoma in Taiwan.
     J Hepatol. 2021 Mar 6. pii: S0168-8278(21)00163.
     PubMed     Abstract available
     
     
     
244. CHENG ST, Hu JL, Ren JH, Yu HB, et al
     Dicoumarol, an NQO1 inhibitor, blocks cccDNA transcription by promoting degradation of HBx.
     J Hepatol. 2021;74:522-534.
     PubMed     Abstract available
     
     
     February 2021
245. LIEBE R, Esposito I, Bock HH, Dahl SV, et al
     Diagnosis and management of secondary causes of steatohepatitis.
     J Hepatol. 2021 Feb 9. pii: S0168-8278(21)00096.
     PubMed     Abstract available
     
     
     
246. IOANNOU GN
     HCC surveillance after SVR in patients with F3/F4 fibrosis.
     J Hepatol. 2021;74:458-465.
     PubMed     Abstract available
     
     
     January 2021
247. SRIDHAR S, Situ J, Cai JP, Yip CC, et al
     Multimodal investigation of rat hepatitis E virus antigenicity: implications for infection, diagnostics, and vaccine efficacy.
     J Hepatol. 2021 Jan 15. pii: S0168-8278(21)00013.
     PubMed     Abstract available
     
     
     November 2020
248. TREBICKA J, Fernandez J, Papp M, Caraceni P, et al
     PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis.
     J Hepatol. 2020 Nov 20. pii: S0168-8278(20)33772.
     PubMed     Abstract available
     
     
     October 2020
249. WANG H, Wen B, Chang X, Wu Q, et al
     Baveno VI criteria and spleen stiffness measurement rule out high-risk varices in virally suppressed HBV-related cirrhosis.
     J Hepatol. 2020 Oct 8. pii: S0168-8278(20)33678.
     PubMed     Abstract available
     
     
     March 2020
250. BUTT AA, Yan P, Shaikh OS, Lo Re V 3rd, et al
     Treatment of HCV reduces viral hepatitis-associated liver-related mortality in patients: An ERCHIVES study.
     J Hepatol. 2020 Mar 4. pii: S0168-8278(20)30120.
     PubMed     Abstract available
     
     
     February 2020
251. HAN JW, Sung PS, Hong SH, Lee H, et al
     IFNL3-adjuvanted HCV DNA vaccine reduces regulatory T-cell frequency and increases virus-specific T-cell responses.
     J Hepatol. 2020 Feb 20. pii: S0168-8278(20)30107.
     PubMed     Abstract available
     
     
     
252. YEH ML, Huang CF, Huang CI, Holmes JA, et al
     Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV/HCV co-infection.
     J Hepatol. 2020 Feb 13. pii: S0168-8278(20)30074.
     PubMed     Abstract available
     
     
     
253. LAMPERTICO P, Carrion JA, Curry M, Turnes J, et al
     Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: a meta-analysis.
     J Hepatol. 2020 Feb 12. pii: S0168-8278(20)30072.
     PubMed     Abstract available
     
     
     
254. VIBERT E, Schwartz M, Olthoff KM
     Advances in resection and transplantation for hepatocellular carcinoma.
     J Hepatol. 2020;72:262-276.
     PubMed     Abstract available
     
     
     
255. SINGAL AG, Lampertico P, Nahon P
     Epidemiology and surveillance for hepatocellular carcinoma: New trends.
     J Hepatol. 2020;72:250-261.
     PubMed     Abstract available
     
     
     January 2020
256. TSENG TC, Liu CJ, Chang CT, Su TH, et al
     HEV superinfection accelerates disease progression in patients with chronic HBV infection and increases mortality in those with cirrhosis.
     J Hepatol. 2020 Jan 29. pii: S0168-8278(20)30029.
     PubMed     Abstract available
     
     
     December 2019
257. HOORNENBORG E, Coyer L, Boyd A, Alfons Achterbergh RC, et al
     High incidence of HCV in HIV-negative men who have sex with men using pre-exposure prophylaxis.
     J Hepatol. 2019 Dec 17. pii: S0168-8278(19)30719.
     PubMed     Abstract available
     
     
     
258. AVERHOFF F, Shadaker S, Gamkrelidze A, Kuchuloria T, et al
     Progress and Challenges in a Pioneering Hepatitis C Elimination Program in the Country of Georgia, 2015-2018.
     J Hepatol. 2019 Dec 4. pii: S0168-8278(19)30710.
     PubMed     Abstract available
     
     
     November 2019
259. LIU CH, Lee MH, Lin JW, Liu CJ, et al
     Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct acting antivirals.
     J Hepatol. 2019 Nov 29. pii: S0168-8278(19)30701.
     PubMed     Abstract available
     
     
     
260. BRASHER NA, Eltahla AA, Underwood A, Boo I, et al
     B cell immunodominance in primary hepatitis C virus infection.
     J Hepatol. 2019 Nov 27. pii: S0168-8278(19)30698.
     PubMed     Abstract available
     
     
     
261. HAJARIZADEH B, Cunningham EB, Valerio H, Martinello M, et al
     Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis.
     J Hepatol. 2019 Nov 27. pii: S0168-8278(19)30699.
     PubMed     Abstract available
     
     
     
262. SHIHA G, Soliman R, Mikhail NN, Easterbrook P, et al
     Educate, Test and Treat Model towards elimination of hepatitis C infection in Egypt: Feasibility and effectiveness in 73 villages.
     J Hepatol. 2019 Nov 14. pii: S0168-8278(19)30672.
     PubMed     Abstract available
     
     
     
263. HAMMOUTENE A, Biquard L, Lasselin J, Kheloufi M, et al
     A defect in endothelial autophagy occurs in patients with nonalcoholic steatohepatitis and promotes inflammation and fibrosis.
     J Hepatol. 2019 Nov 11. pii: S0168-8278(19)30669.
     PubMed     Abstract available
     
     
     
264. BROWN RS JR, Buti M, Rodrigues L, Chulanov V, et al
     Glecaprevir/pibrentasvir for 8 weeks in treatment-naive patients with chronic HCV genotypes 1-6 and compensated cirrhosis: the EXPEDITION-8 trial.
     J Hepatol. 2019 Nov 1. pii: S0168-8278(19)30647.
     PubMed     Abstract available
     
     
     October 2019
265. DORE GJ, Feld JJ, Thompson A, Martinello M, et al
     Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial.
     J Hepatol. 2019 Oct 23. pii: S0168-8278(19)30612.
     PubMed     Abstract available
     
     
     
266. PONS M, Rodriguez-Tajes S, Esteban JI, Marino Z, et al
     Non-invasive prediction of liver related events in HCV compensated advanced chronic liver disease patients after oral antivirals.
     J Hepatol. 2019 Oct 17. pii: S0168-8278(19)30606.
     PubMed     Abstract available
     
     
     
267. LI Y, Tang L, Guo L, Chen C, et al
     CXCL13-mediated recruitment of intrahepatic CXCR5+CD8+T cells favors viral control in chronic HBV infection.
     J Hepatol. 2019 Oct 11. pii: S0168-8278(19)30602.
     PubMed     Abstract available
     
     
     September 2019
268. CLEMENTS O, Eliahoo J, Un Kim J, Taylor-Robinson SD, et al
     Risk Factors for Intrahepatic and Extrahepatic Cholangiocarcinoma: a systematic review and meta-analysis.
     J Hepatol. 2019 Sep 16. pii: S0168-8278(19)30543.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis is free of charge.